Forbes Ranks BioMarin 10th Most Innovative Company in the World
August 24 2016 - 9:54AM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it
has been ranked 10th on Forbes magazine's 2016 list of the "World's
Most Innovative Companies." This is the third consecutive year that
BioMarin has received the recognition, acknowledging the company’s
ongoing commitment to rapidly developing and delivering
first-in-class or best-in-class therapies for those with severe or
life-threatening rare diseases. Last year, the company was also
ranked 10th, and in 2014, the company ranked 7th.
“For nearly 20 years, BioMarin has been committed to making a
big impact in the lives of small patient populations. We are
pioneers in developing medicine for rare genetic diseases. We
push the boundaries of science to change the course of devastating
diseases," said Jean-Jacques Bienaimé, Chairman and Chief Executive
Officer of BioMarin. “We are humbled to once again be recognized as
a leader in innovation by Forbes. We look forward to continuing to
provide underserved patients with treatment options that can make a
meaningful difference in their lives.”
Rankings are based on what Forbes calls the companies'
"innovation premium," the difference between their market
capitalization and a net present value of cash flows from current
businesses. Forbes' method relies on investors' ability to identify
companies they expect to be innovative now and in the future. The
recognition only includes businesses that have at least seven years
of financial data and a market value greater than $10 billion, and
have measurable investment in research and development.
To view the complete list, click here.
About BioMarinBioMarin is a global
biotechnology company that develops and commercializes innovative
therapies for people with serious and life-threatening rare
disorders. The company's portfolio consists of five commercialized
products and multiple clinical and pre-clinical product
candidates.
For additional information, please visit www.BMRN.com.
Information on BioMarin's website is not incorporated by reference
into this press release.
Contact:
Investors:
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media:
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024